Accordingly, the ANVISA‐approved bulas assert (i) “if the (CFTR) genotype is unknown, an exact and validated genoyping method should be performed prior to initiate treatment with ivacaftor” and (ii) “due to the risk of haemolysis in patients with G6PD deficiency or unknown G6PD status”, G6PD testing must be performed prior to prescription of tafenquine; the author classified both assertives as “PGx testing required”. Here, CFTR is linked to hyperinsulinemic hypoglycemia, familial, 4.